Brief: Genprex Announces First Patient Dosed In Phase 2A Expansion Of Acclaim-1

Genprex

05/02/2024 12:42

Feb 5 (Reuters) - Genprex Inc  GNPX.O :
    * GENPREX ANNOUNCES FIRST PATIENT DOSED IN PHASE 2A
EXPANSION OF
ACCLAIM-1 CLINICAL STUDY OF REQORSA® THERAPY IN COMBINATION WITH
TAGRISSO® TO TREAT NON-SMALL CELL LUNG CANCER
    * GENPREX INC - EXPECTS TO COMPLETE ENROLLMENT OF PHASE 2A
EXPANSION STUDY BY END OF 2024
    * GENPREX INC: EXPECTS TO COMPLETE ENROLLMENT OF PHASE 2A
EXPANSION STUDY BY END OF 2024 ;ACCLAIM-1 STUDY HAS FDA FAST
TRACK DESIGNATION

Source text for Eikon:  ID:nPn3B1QLra 
Further company coverage:  GNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))